Funding
Open Access funding enabled and organized by Projekt DEAL. The study was funded by URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany and CEBINA GmbH Vienna, Austria. URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany is the sponsor of the clinical trial. We acknowledge support for the Article Processing Charge from the DFG (German Research Foundation, 491454339).